MacroGenics | MGNX - Debt

Stock Price
1.76
Daily Change
-0.24 -12.00%
Monthly
19.73%
Yearly
-48.99%
Q3 Forecast
1.98

MacroGenics reported $37.25M in Debt for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 245.42M
Cash and Equivalent USD 130.69M
Cost of Sales USD 49.7M
Current Assets USD 204.94M
Current Liabilities USD 39M
Debt USD 37.25M
EBIT USD -35.34M
EBITDA USD -33.44M
Employees 339
EPS Earnings Per Share USD -0.57
Equity Capital and Reserves USD 46.62M
Gross Profit on Sales USD -27.46M
Interest Expense on Debt USD 802K
Interest Income USD 1.41M
Loan Capital USD 70.26M
Market Capitalization USD 124.9M
Net Income USD -36.25M
Operating Expenses USD 59M
Operating Profit USD -36.76M
Ordinary Share Capital USD 63.21M
Pre-Tax Profit USD -36.15M
Sales Revenues USD 22.24M
Selling and Administration Expenses USD 9.3M
Stock USD 9.28M
Trade Creditors USD 4.66M
Trade Debtors USD 12.53M

Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Amgen USD 56.2B 1.18B Jun/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Daiichi Sankyo JPY 101.33B 97M Mar/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Genmab DKK 148M 5M Jun/2025
Geron USD 121.84M 3.12M Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
MacroGenics USD 37.25M 37.25M Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Xencor USD 67.93M 86.45M Jun/2025